A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Novartis
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of Alabama at Birmingham
Ossium Health, Inc.
NextCure, Inc.
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
University of Arizona
Massachusetts General Hospital
Bristol-Myers Squibb
BlossomHill Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Celgene
Novartis
M.D. Anderson Cancer Center
Cyclacel Pharmaceuticals, Inc.
University of Chicago
Ipsen
Zhujiang Hospital
City of Hope Medical Center
Weill Medical College of Cornell University
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Baylor College of Medicine
Taiga Biotechnologies, Inc.
Bayer
Cyclacel Pharmaceuticals, Inc.
Icahn School of Medicine at Mount Sinai
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Bellicum Pharmaceuticals
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
University of Miami
Celgene
Daiichi Sankyo
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Wisconsin, Madison
University College, London
National Cancer Institute (NCI)
University of Maryland, Baltimore
University of Pittsburgh
Dana-Farber Cancer Institute
University of Washington
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center